(Q40423824)

20 September 2017

1 reference

title

CPT-11 (irinotecan) in the treatment of colorectal cancer (English)

1 reference

20 September 2017

CPT-11 (Irinotecan) in the treatment of colorectal cancer (English)

1 reference

https://api.crossref.org/works/10.1016/0959-8049(95)00212-2

19 May 2024

1 reference

1 reference

J. P. Armand

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7577037

19 May 2024

M. Ducreux

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7577037

19 May 2024

M. Mahjoubi

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7577037

19 May 2024

D. Abigerges

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7577037

19 May 2024

R. Bugat

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7577037

19 May 2024

G. Chabot

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7577037

19 May 2024

P. Herait

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7577037

19 May 2024

M. de Forni

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7577037

19 May 2024

P. Rougier

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7577037

19 May 2024

language of work or name

1 reference

1 July 1995

1 reference

full work available at URL

20 September 2017

https://api.elsevier.com/content/article/PII:0959804995002122?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/0959-8049(95)00212-2

https://api.elsevier.com/content/article/PII:0959804995002122?httpAccept=text/plain

19 May 2024

1 reference

https://api.crossref.org/works/10.1016/0959-8049(95)00212-2

European Journal of Cancer

19 May 2024

published in

1 reference

20 September 2017

volume

31A

1 reference

20 September 2017

issue

7-8

1 reference

20 September 2017

page(s)

1283-1287

1 reference

The chemotherapy of colon cancer can no longer be ignored

20 September 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1016/0959-8049(95)00212-2

Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project

19 May 2024

2

1 reference

https://api.crossref.org/works/10.1016/0959-8049(95)00212-2

Meta-analysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer. Advanced Colorectal Cancer Meta-Analysis Project

19 May 2024

3

1 reference

https://api.crossref.org/works/10.1016/0959-8049(95)00212-2

Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomized trial

19 May 2024

4

1 reference

https://api.crossref.org/works/10.1016/0959-8049(95)00212-2

Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer

19 May 2024

5

1 reference

https://api.crossref.org/works/10.1016/0959-8049(95)00212-2

Interferon alpha-2a and 5-fluorouracil for advanced colorectal carcinoma. Assessment of activity and toxicity.

19 May 2024

6

1 reference

https://api.crossref.org/works/10.1016/0959-8049(95)00212-2

Phase II study of fluorouracil and recombinant interferon alfa-2a in previously untreated advanced colorectal carcinoma

19 May 2024

7

1 reference

https://api.crossref.org/works/10.1016/0959-8049(95)00212-2

Phase II trial of fluorouracil and recombinant interferon alfa-2a in patients with advanced colorectal carcinoma: an Eastern Cooperative Oncology Group study

19 May 2024

8

1 reference

https://api.crossref.org/works/10.1016/0959-8049(95)00212-2

Topoisomerase I inhibitors: topotecan and irenotecan

19 May 2024

12

1 reference

https://api.crossref.org/works/10.1016/0959-8049(95)00212-2

Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials

19 May 2024

14

1 reference

https://api.crossref.org/works/10.1016/0959-8049(95)00212-2

DNA topoisomerases: essential enzymes and lethal targets

19 May 2024

15

1 reference

https://api.crossref.org/works/10.1016/0959-8049(95)00212-2

19 May 2024

DNA topoisomerases

16

1 reference

https://api.crossref.org/works/10.1016/0959-8049(95)00212-2

DNA topoisomerase I--targeted chemotherapy of human colon cancer in xenografts

19 May 2024

17

1 reference

https://api.crossref.org/works/10.1016/0959-8049(95)00212-2

Camptothecin overcomes MDR1-mediated resistance in human KB carcinoma cells

19 May 2024

20

1 reference

https://api.crossref.org/works/10.1016/0959-8049(95)00212-2

Activity of CPT-11 (irinotecan hydrochloride), a topoisomerase I inhibitor, against human tumor colony-forming units

19 May 2024

21

1 reference

https://api.crossref.org/works/10.1016/0959-8049(95)00212-2

Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients

19 May 2024

24

1 reference

https://api.crossref.org/works/10.1016/0959-8049(95)00212-2

Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumors

19 May 2024

25

1 reference

https://api.crossref.org/works/10.1016/0959-8049(95)00212-2

Phase I Study of Weekly Intravenous Infusions of CPT-11, a New Derivative of Camptothecin, in the Treatment of Advanced Non-Small-Cell Lung Cancer

19 May 2024

27

1 reference

https://api.crossref.org/works/10.1016/0959-8049(95)00212-2

Phase I Study and Pharmacokinetics of CPT-11 With 5-Day Continuous Infusion

19 May 2024

28

1 reference

https://api.crossref.org/works/10.1016/0959-8049(95)00212-2

Phase I and pharmacokinetic trial of weekly CPT-11

19 May 2024

29

1 reference

https://api.crossref.org/works/10.1016/0959-8049(95)00212-2

Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials

19 May 2024

31

1 reference

https://api.crossref.org/works/10.1016/0959-8049(95)00212-2

Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea

19 May 2024

32

1 reference

https://api.crossref.org/works/10.1016/0959-8049(95)00212-2

Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. CPT-11 Gastrointestinal Cancer Study Group.

19 May 2024

37

1 reference

https://api.crossref.org/works/10.1016/0959-8049(95)00212-2

Simultaneous administration of CPT-11 and fluorouracil: alteration of the pharmacokinetics of CPT-11 and SN-38 in patients with advanced colorectal cancer

19 May 2024

41

1 reference

https://api.crossref.org/works/10.1016/0959-8049(95)00212-2

19 May 2024

Identifiers

1 reference

20 September 2017

1 reference